ANIX

SEC Filing Summary: CopyTele, Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended January 31, 2002. The registrant is CopyTele, Inc., a Delaware corporation (not Anixa Biosciences Inc., as indicated in the metadata request). The company focuses on two primary operations: the development and marketing of hardware-based digital encryption products and a joint venture with Futaba Corporation to develop Field Emission Display (FED) technology. During this quarter, the company ceased reporting as a development-stage enterprise.

Key Financial Metrics

Margins: Gross margin for the quarter was approximately 66.6%. The company reported a net profit margin of 4.7%.

Debt and Liquidity: The company has no long-term debt listed on the balance sheet. Current liabilities total $4,113,535, primarily driven by deferred revenue. Liquidity improved significantly due to a $3 million payment received from Futaba Corporation.

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased by approximately $1.1 million (616% increase) year-over-year. This was driven by $1.033 million in revenue recognized from the Futaba collaborative agreement, compared to zero in the prior year. Product sales revenue increased modestly by $66,000.
• Profitability Turnaround: The company shifted from a net loss of $1.13 million in Q1 2001 to a net income of $60,307 in Q1 2002. This turnaround is largely attributable to the Futaba payments and a reclassification of certain R&D costs to Cost of Revenue.
• Expense Reduction: Research and Development expenses decreased by $340,000, and Selling, General, and Administrative (SG&A) expenses decreased by $107,000. The SG&A reduction included a $60,000 recovery of a previously recorded bad debt charge.
• Cash Position: Cash and cash equivalents more than doubled from $1.32 million to $3.45 million, primarily due to the $3 million cash inflow from Futaba.

Guidance, Outlook, and Risks

Outlook and Guidance: Management believes existing cash and receivables are sufficient to fund operations until at least the end of the first quarter of fiscal 2003. Future funding may be required thereafter. The company expects to recognize approximately $2.425 million and $1.084 million of deferred revenue in the quarters ending April 30, 2002, and July 31, 2002, respectively.

Material Risks and Contingencies:

• Nasdaq Delisting Risk: The company's stock price ($0.45 as of March 11, 2002) is below the $1.00 minimum bid price required for Nasdaq National Market listing. The company faces potential delisting unless the price recovers for 10 consecutive trading days before May 15, 2002.
• Dependency on Futaba: Future profitability is heavily dependent on receiving additional payments from Futaba Corporation, which are subject to negotiation and not guaranteed.
• Inventory Realizability: Management notes that sales of encryption products have been limited, and there is no assurance that inventory can be sold at current carrying values.
• Barter Credits: Approximately $2.85 million in assets consists of commercial trade barter credits, the realization of which depends on future product sales growth.

Investor Verification Checklist

• Verify the status of the Nasdaq delisting notice and the company's plan to regain compliance with the $1.00 bid price requirement.
• Confirm the terms and likelihood of future payments from Futaba Corporation beyond the initial $5.5 million received to date.
• Assess the realizability of the $1.5 million inventory and the $2.85 million in barter credits given limited historical sales volume.
• Review the Volga Svet agreement obligations, specifically the upcoming $750,000 payment commitment tied to the Futaba project.
• Monitor the reclassification of R&D costs to Cost of Revenue to ensure it accurately reflects the nature of the expenses and does not artificially inflate gross margins.